10557551

Source:http://linkedlifedata.com/resource/pubmed/id/10557551

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0021267, umls-concept:C0220812, umls-concept:C0376691, umls-concept:C0449911, umls-concept:C0456389, umls-concept:C0872152
pubmed:issue	2
pubmed:dateCreated	1999-9-30
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9215384
pubmed:citationSubset	T
pubmed:status	MEDLINE
pubmed:issn	1064-590X
pubmed:author	pubmed-author:NiblackJ FJF
pubmed:issnType	Print
pubmed:volume	52
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	151-4
pubmed:dateRevised	2004-11-17
pubmed:meshHeading	pubmed-meshheading:10557551-Drug Approval, pubmed-meshheading:10557551-Drug Industry, pubmed-meshheading:10557551-Forecasting, pubmed-meshheading:10557551-Humans, pubmed-meshheading:10557551-Time Factors, pubmed-meshheading:10557551-United States
pubmed:year	1997
pubmed:articleTitle	Why are drug development programs growing in size and cost? A view from industry.
pubmed:affiliation	Pfizer Inc, Groton, CT, USA.
pubmed:publicationType	Journal Article